CN Patent

CN116478141B — 氘代kras抑制剂药物及用途

Assigned to Yaokang Zhongtuo Jiangsu Pharmaceutical Technology Co ltd · Expires 2023-10-24 · 3y expired

What this patent protects

本发明公开了氘代KRAS抑制剂，如下式Ⅰ所示，本发明涉及氘代KRAS抑制剂、其药物组合物及用途，本发明提供一类氘代化合物及其药学上可接受的盐，进一步改善KRAS抑制剂的药代动力学性质，降低给药剂量和可能的毒副作用。

USPTO Abstract

本发明公开了氘代KRAS抑制剂，如下式Ⅰ所示，本发明涉及氘代KRAS抑制剂、其药物组合物及用途，本发明提供一类氘代化合物及其药学上可接受的盐，进一步改善KRAS抑制剂的药代动力学性质，降低给药剂量和可能的毒副作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN116478141B
Jurisdiction
CN
Classification
—
Expires
2023-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Yaokang Zhongtuo Jiangsu Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.